meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced RCC (mRCC) - 2nd line (L2)
2
sarcomas
thyroid cancer
urothelial cancer (UC) - bladder cancer (BC)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus cabozantinib
nivolumab based treatment
nivolumab alone
versus all
vs mTOR inhibitors
vs everolimus
vs VEGF(R) inhibitor
vs cabozantinib
All patients
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
progression or deaths (PFS)
AE (grade 3-4)
AE leading to death (grade 5)
AE leading to treatment discontinuation (any grade)
SAE (any grade)
deaths (OS)
metastatic/advanced RCC (mRCC) - 2nd line (L2)
metastatic/advanced RCC (mRCC) - 2nd line (L2)
versus cabozantinib
atezolizumab plus cabozantinib vs. cabozantinib
1
certainty unassessable
-6%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open